Home > Boards > US Listed > Biotechs > Biohaven Pharmceuticals (BHVN)

I bought at $42.50. I made a lot

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Virginia Prospector Member Profile
 
Followed By 2
Posts 122
Boards Moderated 0
Alias Born 03/10/19
160x600 placeholder
Biohaven names new CEO, CFO Seeking Alpha - 12/6/2021 10:54:35 AM
Biohaven says pivotal study for intranasal migraine therapy met main goals Seeking Alpha - 12/6/2021 9:33:15 AM
Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application PR Newswire (US) - 12/6/2021 7:30:00 AM
Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer PR Newswire (US) - 12/6/2021 7:29:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:34:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:29:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:27:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:27:00 PM
Biohaven, Artizan to work on Parkinson's drug discovery program Seeking Alpha - 11/18/2021 8:23:52 AM
Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease GlobeNewswire Inc. - 11/18/2021 7:30:00 AM
Biohaven's migraine med Nurtec approved in Kuwait Seeking Alpha - 11/17/2021 7:10:54 AM
NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine PR Newswire (US) - 11/17/2021 6:57:00 AM
Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital PR Newswire (US) - 11/15/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/10/2021 6:19:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2021 4:29:29 PM
Biohaven falls 15% on apparent disappointment that Pfizer deal isn't a buyout Seeking Alpha - 11/9/2021 9:06:59 AM
Biohaven, Pfizer in Collaboration to Commercialize Rimegepant Dow Jones News - 11/9/2021 8:47:00 AM
Biohaven Pharmaceuticals EPS beats by $0.11, beats on revenue Seeking Alpha - 11/9/2021 8:33:16 AM
Pfizer to gains ex-U.S. rights to Biohaven migraine med Nurtec in up to $1.24B deal Seeking Alpha - 11/9/2021 8:13:16 AM
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States PR Newswire (US) - 11/9/2021 7:46:00 AM
Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments PR Newswire (US) - 11/9/2021 7:45:00 AM
Biohaven Pharmaceuticals Q3 2021 Earnings Preview Seeking Alpha - 11/8/2021 11:47:53 AM
Biohaven To Report Third Quarter 2021 Financial Results And Recent Business Developments On November 9, 2021 PR Newswire (US) - 11/4/2021 7:30:00 AM
Nine Line Apparel and Biohaven's Nurtec ODT Set to Honor World War II Veterans Ahead of 80th Anniversary at Phoenix Raceway PR Newswire (US) - 11/2/2021 7:30:00 AM
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma PR Newswire (US) - 10/27/2021 7:30:00 AM
Virginia Prospector   Thursday, 02/13/20 11:26:23 AM
Re: Glider549 post# 14
Post # of 21 
I bought at $42.50. I made a lot of money since IPO and believe this company has a lot of potential.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences